Papillary renal cell carcinoma

Active Research Protocols

  1. 07-C-0121 – A Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal-Cell Carcinoma (PRC)
NOTE: PDF documents require the free
Adobe Reader.
This page was last updated: January 24, 2014